Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Files Biosimilar Neulasta In Europe, Praises EMA

This article was originally published in Scrip

Executive Summary

Sandoz, Novartis AG's generic drugs unit, has confirmed it has filed a market authorization application in Europe for a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim) – the company also praised biosimilar registration processes at the EMA.

You may also be interested in...



Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA

Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.

Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA

Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.

Deals Shaping Medtech And Diagnostics, September 2021

Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.

Topics

UsernamePublicRestriction

Register

SC064467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel